Daily Pulsed Magnetic Brain Stimulation Study in Parkinson's Disease
Tests daily pulsed electromagnetic brain stimulation against sham treatment in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: The Effect of Long-term Daily Stimulation of the Brain With Pulsed Electromagnetic Fields on Parkinsons Disease
Key facts
- Where
- Odense, DenmarkSee the 2 sites
Where in Denmark
- Odense University HospitalOdense, DenmarkTaking people
- University of Southern DenmarkOdense, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Southern Denmark
- Trial code
- NCT07306104
- Record updated
- 29 April 2026
- Original description
The goal of this clinical trial is to learn to what extent daily stimulation of the brain with transcranial pulsed electromagnetic fields (T-PEMF) works to treat persons with Parkinson's Disease. The main questions it aims to answer are:Read full original descriptionShow less
The Effect of Long-term Treatment of Parkinson's Disease With T-PEMF
The goal of this clinical trial is to learn to what extent daily stimulation of the brain with transcranial pulsed electromagnetic fields (T-PEMF) works to treat persons with Parkinson's Disease. The main questions it aims to answer are:
* How does 6 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors compared with placebo treatment in persons with Parkinson's disease? * How does 12 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors in persons with Parkinson's disease an does 12 months of T-PEMF alters the need for medication intake?
The neuro-mechanical outcomes are compared with the "natural" progression of the disease as well as with a healthy reference group. Furthermore, it will be examined whether 12 months of T-PEMF treatment alters the need for medication intake.
Participants in the intervention group will:
* receive one 30 min treatment session daily for 12 months * receive either T-PEMF or sham treatment for the first 6 months * receive active T-PEMF treatment the last 6 months * visit for tests before treatment initiation, after 6 months of treatment and after 12 months of treatment.
Inclusion: Diagnosed with idiopathic Parkinson's disease; The participant must be able to understand, accept, and complete the planned procedures; Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2; Mini Mental-State Examination score > 22; Diagnosed with idiopathic Parkinson's disease; The patient must be able to understand, accept, and complete the planned procedures; Parkinson's symptoms in the medicated state must correspond to Hoehn \& Yahr stage 1 or 2; Mini Mental-State Examination score > 22; -The patient must be able to understand, accept, and complete the planned procedures.
Exclusion: Presence of active medical implants; Changes in pharmacological anti-Parkinson medication within the last 6 weeks prior to the start of T-PEMF treatment; Anticoagulant treatment with Marevan, Marcoumar, Pradaxa, Eliquis, Xarelto, Lixiana, Novostan, Fragmin, or Innohep; Previous stroke; Cancer in the brain, neck, or head area; Epilepsy; Severe psychopathological disorders; Neurological disease other than Parkinson's disease; Reduced motor function caused by conditions other than Parkinson's disease; Control Group with Parkinson's Disease; Neurological disease other than Parkinson's disease; Reduced motor function caused by conditions other than Parkinson's disease; Healthy Reference Group:; Neurological disease; Reduced motor function caused by condition; Alcoholism; Substance abuse; Open wound on the scalp; Pregnancy.
Intervention Groups.